Dr. Oliver Sartor Discusses PSA Screening

Oliver Sartor, MD
Published Online: Tuesday, May 22, 2012

Oliver Sartor, MD, medical director, Tulane Cancer Center, explains that he has debated both the pros and cons of prostate-specific antigen (PSA) screening for men with prostate cancer and feels he is able to provide an unbiased opinion on its efficacy.

There is no question that PSA screening detects many cancers that do not need to be treated, Sartor believes. To him, the larger question is whether there is enough knowledge to determine which patients should be treated and which should not.

The root of the PSA question revolves around the use of the score to wisely determine treatment. Sartor notes that PSA results effectively aid the decision process, not perfectly, but reasonably.

Oliver Sartor, MD, medical director, Tulane Cancer Center, explains that he has debated both the pros and cons of prostate-specific antigen (PSA) screening for men with prostate cancer and feels he is able to provide an unbiased opinion on its efficacy.

There is no question that PSA screening detects many cancers that do not need to be treated, Sartor believes. To him, the larger question is whether there is enough knowledge to determine which patients should be treated and which should not.

The root of the PSA question revolves around the use of the score to wisely determine treatment. Sartor notes that PSA results effectively aid the decision process, not perfectly, but reasonably.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Vignette Series: 33rd Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 19, 20173.0
Community Practice Connections™: New York GU™: 9th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary MalignanciesMay 27, 20171.5
Publication Bottom Border
Border Publication